Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J.L. Heerspink, Chris Vercammen, Donald Kohan et al.|The Lancet|2019Cited by 620
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY AnalysisPeter Rossing, Duncan J. Topliss, Stefan D. Anker et al.|Diabetes Care|2022Cited by 207
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 DiabetesRajiv Agarwal, Anantharaman Vathsala, Wanzhu Tu et al.|Annals of Internal Medicine|2023Cited by 94
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD StudyJanusz Gumprecht, Ellen Burgess, Rajiv Agarwal et al.|Diabetes Care|2022Cited by 36